141 related articles for article (PubMed ID: 14758034)
1. Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats.
Shibata N; Kageyama M; Kimura K; Tadano J; Hukushima H; Namiki H; Yoshikawa Y; Takada K
Biol Pharm Bull; 2004 Feb; 27(2):203-9. PubMed ID: 14758034
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
Shibata N; Kageyama M; Kishida T; Kimura K; Yoshikawa Y; Kuwahara T; Toh J; Shirasaka T; Takada K
Biopharm Drug Dispos; 2003 Nov; 24(8):335-44. PubMed ID: 14595702
[TBL] [Abstract][Full Text] [Related]
3. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats.
Usansky HH; Hu P; Sinko PJ
Drug Metab Dispos; 2008 May; 36(5):863-9. PubMed ID: 18256206
[TBL] [Abstract][Full Text] [Related]
4. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
5. Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
Gao W; Kageyama M; Inoue Y; Tadano J; Fukumoto K; Fukushima K; Yamasaki D; Nishimura A; Yoshikawa Y; Shibata N; Takada K
Biol Pharm Bull; 2003 Feb; 26(2):199-204. PubMed ID: 12576680
[TBL] [Abstract][Full Text] [Related]
6. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.
Su Y; Zhang X; Sinko PJ
Mol Pharm; 2004 Jan; 1(1):49-56. PubMed ID: 15832500
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits.
Sinko PJ; Kunta JR; Usansky HH; Perry BA
J Pharmacol Exp Ther; 2004 Jul; 310(1):359-66. PubMed ID: 15004217
[TBL] [Abstract][Full Text] [Related]
8. Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats.
Li J; Liu Y; Zhang J; Yu X; Wang X; Zhao L
Drug Des Devel Ther; 2016; 10():3699-3706. PubMed ID: 27895462
[TBL] [Abstract][Full Text] [Related]
9. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.
Jain R; Duvvuri S; Kansara V; Mandava NK; Mitra AK
Int J Pharm; 2007 May; 336(2):233-40. PubMed ID: 17207946
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation.
He Y; Xia DN; Li QX; Tao JS; Gan Y; Wang C
Acta Pharmacol Sin; 2015 Sep; 36(9):1151-60. PubMed ID: 26256404
[TBL] [Abstract][Full Text] [Related]
11. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
12. Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation.
Pathak SM; Musmade P; Dengle S; Karthik A; Bhat K; Udupa N
Eur J Pharm Sci; 2010 Nov; 41(3-4):440-51. PubMed ID: 20656025
[TBL] [Abstract][Full Text] [Related]
13. In situ study of the effect of naringin, talinolol and protein-energy undernutrition on intestinal absorption of saquinavir in rats.
Catalán-Latorre A; Nácher A; Merino V; Jiménez-Torres NV; Merino-Sanjuán M
Basic Clin Pharmacol Toxicol; 2011 Oct; 109(4):245-52. PubMed ID: 21535410
[TBL] [Abstract][Full Text] [Related]
14. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
15. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.
Washington CB; Wiltshire HR; Man M; Moy T; Harris SR; Worth E; Weigl P; Liang Z; Hall D; Marriott L; Blaschke TF
Drug Metab Dispos; 2000 Sep; 28(9):1058-62. PubMed ID: 10950849
[TBL] [Abstract][Full Text] [Related]
16. Reduced Oral Bioavailability and Altered Pharmacokinetics of Saquinavir by Co-administration with Biochanin A in Rats.
Li J; Liu Y; Yu X; Zhang J; Gu J; Zhao L
Drug Res (Stuttg); 2016 Sep; 66(9):484-488. PubMed ID: 27409329
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir.
Wang Z; Pal D; Mitra AK
J Pharm Sci; 2012 Sep; 101(9):3199-213. PubMed ID: 22611042
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
19. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
[TBL] [Abstract][Full Text] [Related]
20. Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux.
Jain R; Agarwal S; Mandava NK; Sheng Y; Mitra AK
Int J Pharm; 2008 Oct; 362(1-2):44-51. PubMed ID: 18620036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]